TP53 and non-small cell lung carcinoma: Of note, a similar percentage (20–24%) of metastatic ALK+ NSCLC has been reported to harbor TP53 mutations at baseline in two recent series [7,8], which adds up to TP53 mutations being detectable in approximately 40–50% of TKI-refractory ALK+ NSCLC patients, as had already been noted in an earlier study [12].